Last reviewed · How we verify
Tretinoin and Pioglitazone HCL
Tretinoin and Pioglitazone HCL is a Small molecule drug developed by Phoenix Neurological Associates, LTD. It is currently in Phase 1 development.
At a glance
| Generic name | Tretinoin and Pioglitazone HCL |
|---|---|
| Sponsor | Phoenix Neurological Associates, LTD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML (PHASE2)
- Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tretinoin and Pioglitazone HCL CI brief — competitive landscape report
- Tretinoin and Pioglitazone HCL updates RSS · CI watch RSS
- Phoenix Neurological Associates, LTD portfolio CI
Frequently asked questions about Tretinoin and Pioglitazone HCL
What is Tretinoin and Pioglitazone HCL?
Tretinoin and Pioglitazone HCL is a Small molecule drug developed by Phoenix Neurological Associates, LTD.
Who makes Tretinoin and Pioglitazone HCL?
Tretinoin and Pioglitazone HCL is developed by Phoenix Neurological Associates, LTD (see full Phoenix Neurological Associates, LTD pipeline at /company/phoenix-neurological-associates-ltd).
What development phase is Tretinoin and Pioglitazone HCL in?
Tretinoin and Pioglitazone HCL is in Phase 1.
Related
- Manufacturer: Phoenix Neurological Associates, LTD — full pipeline